MIROCALS · Project

New Immune-Boosting Therapy Tested in Clinical Trial for ALS Patients

healthTestedTRL 5Thin data (2/5)

ALS is a devastating disease where nerve cells die, partly because the body's own immune system turns against them. Think of regulatory T cells as the body's peacekeepers — in ALS patients, these peacekeepers are weakened and can't stop the damage. MIROCALS tested whether giving patients a low dose of a natural immune signal (interleukin-2) could strengthen these peacekeepers and slow the disease. They ran a proper clinical trial across six countries to see if this approach could finally break through where dozens of other ALS drugs have failed.

By the numbers

40,000

ALS patients in Europe

11,000

ALS deaths per year in Europe

EUR 5,980,435

EU funding for Phase II clinical trial

consortium partners across the trial

countries involved in the trial

The business problem

What needed solving

ALS kills 11,000 Europeans every year and affects 40,000 at any given time, yet only one modestly effective drug (riluzole) exists. Every subsequent drug trial after riluzole has failed, creating a massive unmet medical need and a stalled drug development pipeline. Pharmaceutical and biotech companies need validated new therapeutic targets and proven trial designs to justify investment in ALS.

The solution

What was built

MIROCALS conducted a Phase II randomized controlled trial testing low-dose interleukin-2 as a regulatory T cell enhancer in newly diagnosed ALS patients. The project delivered clinical trial data, a validated biomarker-integrated trial design for ALS, and proof-of-concept evidence for immune modulation as a therapeutic strategy in neurodegeneration.

Audience

Who needs this

Pharmaceutical companies with neurodegenerative disease pipelines looking for validated ALS targetsBiotech firms developing Treg or IL-2-based immunotherapies seeking new indicationsClinical research organizations needing proven ALS trial designs with biomarker endpointsVenture capital and life science investors evaluating ALS therapeutic opportunitiesPatient advocacy organizations funding ALS drug development

Business applications

Who can put this to work

Pharmaceuticals

enterprise

Target: Pharma companies with neurodegenerative disease pipelines

If you are a pharmaceutical company struggling with failed ALS drug candidates — this project ran a Phase II clinical trial testing low-dose IL-2 as a Treg-boosting therapy across 15 partners in 6 countries. The trial design integrates biomarkers for early proof-of-concept, which could de-risk your own ALS pipeline by validating immune modulation as a therapeutic target. With 40,000 ALS patients in Europe and no effective treatment beyond riluzole, a validated approach opens a significant market opportunity.

Biotechnology

any

Target: Biotech firms developing immunotherapy or Treg-based treatments

If you are a biotech company working on regulatory T cell therapies for autoimmune or inflammatory conditions — MIROCALS demonstrated that low-dose IL-2 can be applied to neurodegeneration, not just diabetes or graft-versus-host disease. The project built clinical evidence and biomarker protocols across a consortium of 15 partners. This expands the addressable market for your Treg-modulating platform into neurodegenerative diseases affecting 40,000 people in Europe.

Clinical Research Services

mid-size

Target: CROs specializing in neurodegenerative disease trials

If you are a clinical research organization that runs trials for neurological conditions — MIROCALS developed a re-engineered trial design for ALS including novel biomarker endpoints from blood and cerebrospinal fluid. Traditional ALS trial designs have consistently failed to detect drug effects. This validated methodology, tested across 6 countries with EUR 5,980,435 in EU funding, could become your competitive advantage when pitching ALS trial services to pharma sponsors.

Frequently asked

Quick answers

What would it cost to license or adopt this therapy approach?

The project was funded with EUR 5,980,435 from the EU under Horizon 2020. Low-dose IL-2 (Proleukin/aldesleukin) is an existing approved drug being repurposed, which significantly reduces development costs compared to new molecules. Licensing terms would need to be negotiated with the coordinator, Centre Hospitalier Universitaire in France.

Can this scale to treat the full ALS patient population?

ALS affects approximately 40,000 individuals in Europe with 11,000 deaths per year. Since ld-IL-2 is already manufactured at scale for other indications, the drug supply chain exists. The main scaling challenge is regulatory approval — the project delivered Phase II proof-of-concept data that would need to feed into a Phase III registration trial.

What is the IP and licensing situation?

The use of low-dose IL-2 for Treg enhancement in ALS may be covered by method-of-use patents filed by the consortium. The coordinator is a French university hospital, and IP ownership likely follows Horizon 2020 grant agreement rules where each partner owns their foreground IP. Contact the coordinator for licensing details.

Where does this stand in the regulatory approval process?

MIROCALS was a Phase II randomized controlled trial providing proof of concept and proof of mechanism. This is roughly mid-stage in the drug approval pathway. A Phase III trial would still be needed before any regulatory submission to EMA or FDA, which typically requires additional years and significant investment.

What was the project timeline and current status?

The project ran from September 2015 to September 2021 (six years) and is now closed. Results from the Phase II trial are available through the consortium. Any company interested in advancing this therapy would be building on completed clinical data rather than starting from scratch.

How does this fit with existing ALS treatment pipelines?

Currently riluzole is the only disease-modifying treatment for ALS, and it offers modest benefit. MIROCALS targets a completely different mechanism — immune regulation through Tregs rather than glutamate modulation. This makes it complementary to existing approaches and potentially combinable with other pipeline candidates.

Consortium

Who built it

The MIROCALS consortium is notably strong with 15 partners across 6 countries (Germany, France, Ireland, Italy, Sweden, UK), giving it broad European clinical reach. With 7 industry partners (47% industry ratio) alongside 5 universities and 2 research organizations, the project had serious commercial intent — not just academic curiosity. The coordinator is a French university hospital (Centre Hospitalier Universitaire), which is typical for clinical trials where hospital infrastructure is essential. The presence of only 1 SME suggests this is big-pharma territory rather than a startup play. For a business looking to license or co-develop, the multi-country clinical network is a ready-made infrastructure for any follow-up Phase III trial.

ICON CLINICAL RESEARCH (U.K.) LIMITEDthirdparty · UK
THE UNIVERSITY OF SHEFFIELDparticipant · UK
ICON CLINICAL RESEARCH LIMITEDparticipant · IE
ICON CLINICAL RESEARCH GMBHthirdparty · DE
THE UNIVERSITY OF SUSSEXparticipant · UK
INSERM TRANSFERT SAparticipant · FR
HUMANITAS MIRASOLE SPAparticipant · IT
QUEEN MARY UNIVERSITY OF LONDONparticipant · UK
ASSOCIATION GENETHONparticipant · FR
GOETEBORGS UNIVERSITETparticipant · SE
KING'S COLLEGE LONDONparticipant · UK

How to reach the team

Centre Hospitalier Universitaire (France) — contact via CORDIS project page or MND Association website

Order a report on this consortium

Next steps

Talk to the team behind this work.

Want an introduction to the MIROCALS clinical team? SciTransfer can connect you with the right people to discuss licensing, trial data access, or Phase III collaboration.

Order a report on this topic More in Health & Biomedical